AGEN

Agenus Inc. operates as a clinical-stage immuno-oncology company focused on discovering and developing therapies that engage the immune system to fight cancer. Headquartered in Lexington, Massachusetts, the company advances a portfolio of checkpoint antibodies, adoptive cell therapies, and adjuvant platforms designed to activate immune response against tumors. Agenus develops its proprietary technologies through two primary segments: its antibody discovery platform, which includes multiple checkpoint modulators in clinical trials, and its cell therapy division focusing on personalized and allogeneic approaches. The company's pipeline features botensilimab, an Fc-enhanced CTLA-4 antibody being studied in combination with balstilimab, a PD-1 inhibitor, across various solid tumors. Agenus also maintains MiNK Therapeutics as a majority-owned subsidiary specializing in allogeneic invariant natural killer T-cell therapies. The company employs approximately 300 people and operates manufacturing facilities supporting both antibody and cell therapy production. Recent developments include advancing multiple Phase 2 clinical trials in colorectal cancer, ovarian cancer, and other indications, while actively pursuing strategic partnerships to expand its development capabilities. Agenus generates revenue primarily through research collaborations and licensing agreements with pharmaceutical partners. The company competes in the increasingly crowded immuno-oncology space alongside both established pharmaceutical companies and emerging biotechnology firms developing next-generation cancer immunotherapies.